Based on the ODYSSEY Outcomes Trial, specifically the low LDL-C levels achieved without adverse consequences, what target level of LDL-C do you recommend in medically managed patients with moderate-to-high risk features of ASCVD?

Based on the ODYSSEY Outcomes Trial, specifically the low LDL-C levels achieved without adverse consequences, what target level of LDL-C do you recommend in medically managed patients with moderate-to-high risk features of ASCVD?

http://cmr.2.2.broadcastmed.net/videos/from-a-medical-cardiologist-s-perspective-which-patient-subgroups-in-your-practice-do-you-feel-represent-ideal-candidates-for-deployment-of-pcsk9-inhibitors-to-lower-ldl-c-levels-based-on-the-results-of-the-odyssey-outcomes-and-fourier-t/flushcache/1/showdraft/1


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Robert Rosenson, MD

Robert Rosenson, MD

Professor of Medicine (Cardiology) Mount Sinai Icahn School of Medicine Director, Cardiometabolics Unit Mount Sinai Heart Institute New York, NY